Nanda Subhash, Bansal Manish K, Singh Priya, Shrivastav Ashish K, Malav Manoj K, Prakash Chandra
Medicine, Sarojini Naidu Medical College, Agra, IND.
Internal Medicine, Sarojini Naidu Medical College, Agra, IND.
Cureus. 2024 Nov 26;16(11):e74522. doi: 10.7759/cureus.74522. eCollection 2024 Nov.
Tuberculosis (TB) continues to be a major health concern that has a significant impact on morbidity and mortality worldwide. Tubercular meningitis (TBM) may be fatal due to its severe neurological outcomes if not diagnosed and treated promptly. The newer molecular diagnostic techniques have brought significant advancements in the detection of (MTB). One such test is the cerebrospinal fluid (CSF)-Truenat assay which offers several advantages over traditional methods and provides results within a few hours. This is crucial for timely intervention and can further improve patient outcomes. We have evaluated its diagnostic accuracy, its utility, and its usefulness in treatment decisions.
A cross-sectional study was conducted on 150 patients. The CSF samples were analyzed by both cartridge-based nucleic acid amplification test (CBNAAT) and Truenat (Molbio Diagnostics Private Limited, Verna, Goa, India). Brain imaging was also performed. Patients were divided into four groups, i.e., definite, probable, possible, and non-TBM. Truenat-positive cases were considered definite, and their efficacy and clinical utility for diagnosing and managing TBM were compared with CBNAAT.
A comparative analysis between CBNAAT and Truenat showed concordance for positive results. But it also identified some discrepancies, particularly in cases where CBNAAT was positive and Truenat was negative. Overall, Truenat demonstrated strong diagnostic performance with a sensitivity of 83.75%, a specificity of 88.57%, and overall accuracy of 86% as compared to CBNAAT.
The study highlighted the role of Truenat in improving diagnostic accuracy and guiding cost-effective treatment strategies for TBM as compared to CBNAAT. As molecular tests alone cannot detect bacilli in most cases, a combination of clinical, microbiological, and radiological parameters is also obligatory for diagnosing TBM.
结核病仍然是一个重大的健康问题,对全球的发病率和死亡率有重大影响。结核性脑膜炎(TBM)如果不及时诊断和治疗,可能因其严重的神经学后果而致命。更新的分子诊断技术在结核分枝杆菌(MTB)的检测方面带来了重大进展。其中一项检测是脑脊液(CSF)-TrueNat检测,它比传统方法有几个优势,并且能在几小时内得出结果。这对于及时干预至关重要,并且可以进一步改善患者的治疗效果。我们评估了其诊断准确性、实用性以及在治疗决策中的有用性。
对150名患者进行了一项横断面研究。脑脊液样本通过基于试剂盒的核酸扩增检测(CBNAAT)和TrueNat(印度果阿韦尔纳的Molbio诊断私人有限公司)进行分析。还进行了脑部成像。患者被分为四组,即确诊、很可能、可能和非TBM组。TrueNat阳性的病例被视为确诊,并且将其在诊断和管理TBM方面的疗效和临床实用性与CBNAAT进行了比较。
CBNAAT和TrueNat之间的比较分析显示阳性结果具有一致性。但也发现了一些差异,特别是在CBNAAT为阳性而TrueNat为阴性的病例中。总体而言,与CBNAAT相比,TrueNat表现出强大的诊断性能,灵敏度为83.75%,特异性为88.57%,总体准确率为86%。
该研究强调了与CBNAAT相比,TrueNat在提高TBM诊断准确性和指导具有成本效益的治疗策略方面的作用。由于在大多数情况下仅靠分子检测无法检测到杆菌,因此临床、微生物学和放射学参数的综合对于诊断TBM也是必不可少的。